Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||SRSF2 mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SRSF2 mutant||polycythemia vera||not applicable||N/A||Guideline||Prognostic||SRSF2 mutations are associated with inferior overall survival in patients with polycythemia vera (NCCN.org).||detail...|
|SRSF2 mutant||acute myeloid leukemia||predicted - sensitive||CG-806||Preclinical - Patient cell culture||Actionable||In a preclinical study, patient-derived acute myeloid leukemia cells harboring SRSF2 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).||detail...|
|SRSF2 mutant||acute myeloid leukemia||predicted - sensitive||GSK3203591||Preclinical - Patient cell culture||Actionable||In a preclinical study, patient-derived acute myeloid leukemia cell lines harboring mutations in U2AF1 (n=3), SRSF2 (n=9), or SF3B1 (n=4) demonstrated increased sensitivity to GSK3203591 compared to spliceosomal wild-type cell lines in culture (PMID: 31408619).||31408619|
|SRSF2 mutant||essential thrombocythemia||not applicable||N/A||Guideline||Prognostic||The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SRSF2, SF3B1, EZH2, TP53, or RUNX1 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).||detail...|
|SRSF2 mutant||myelofibrosis||not applicable||N/A||Guideline||Prognostic||SRSF2 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).||detail...|
|SRSF2 mutant||myelofibrosis||not applicable||N/A||Guideline||Diagnostic||SRSF2 mutations aid in the diagnosis of primary myelofibrosis in the absence of JAK2, CALR, or MPL mutations (NCCN.org).||detail...|
|SRSF2 mutant||myelodysplastic syndrome||not applicable||N/A||Clinical Study||Prognostic||In multiple clinical studies, SRSF2 mutations were associated with shortened survival in patients with myelodysplastic syndrome (PMID: 26769228, PMID: 26508027).||26508027 26769228|
|SRSF2 mutant||chronic myelomonocytic leukemia||sensitive||H3B-8800||Preclinical - Pdx||Actionable||In a preclinical study, H3B-8800 inhibited tumor growth in patient-derived xenograft (PDX) models of chronic myelomonocytic leukemia harboring SRSF2 mutations, but not in SRSF2 wild-type PDX models (PMID: 29457796).||29457796|